← All trials
NCT04466540
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 12, 2020
- Primary completion
- Jan 28, 2021
- Completion date
- Mar 30, 2021
- First posted
- Jul 10, 2020
- Last posted
- Nov 27, 2020
- Enrollment
- 1300
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Oswaldo Cruz FoundationLead sponsor
- EMS S/ACollaborator
- Albert Einstein Israelite HospitalCollaborator
- Hospital Sirio-LibanesCollaborator
- Hospital Moinhos de VentoCollaborator
- Hospital do CoracaoCollaborator
- Brazilian Research In Intensive Care NetworkCollaborator
- Oswaldo Cruz FoundationReponsible party - principal investigator
- Oswaldo Cruz FoundationOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.